Gilead­'s sto­ried hep C fran­chise will now in­clude a gener­ic drug op­er­a­tion

Faced with a dwin­dling stream of rev­enue for its he­pati­tis C fran­chise amid an on­go­ing na­tion­al de­bate on drug pric­ing, Gilead has come up with an un­con­ven­tion­al plan.

Through a new sub­sidiary named Asegua Ther­a­peu­tics, Gilead will sell gener­ic ver­sions of the he­pati­tis C com­bo drugs Ep­clusa and Har­voni at a price of $24,000 — a frac­tion of the list prices of the drugs, which cost $75,000 and $94,500 re­spec­tive­ly for a 12-week reg­i­men.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.